These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

581 related items for PubMed ID: 12686819

  • 1. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
    Oudard S, Legrier ME, Boyé K, Bras-Gonçalves R, De Pinieux G, De Cremoux P, Poupon MF.
    J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819
    [Abstract] [Full Text] [Related]

  • 2. A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer.
    Dahmani A, de Plater L, Guyader C, Fontaine JJ, Berniard A, Assayag F, Beuzeboc P, Marangoni E, Némati F, Poupon MF, Pasik C, Oudard S, Decaudin D.
    Anticancer Drugs; 2010 Nov; 21(10):927-31. PubMed ID: 20827173
    [Abstract] [Full Text] [Related]

  • 3. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
    Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED.
    N Engl J Med; 2004 Oct 07; 351(15):1513-20. PubMed ID: 15470214
    [Abstract] [Full Text] [Related]

  • 4. Future directions in the treatment of androgen-independent prostate cancer.
    Petrylak DP.
    Urology; 2005 Jun 07; 65(6 Suppl):8-12. PubMed ID: 15939077
    [Abstract] [Full Text] [Related]

  • 5. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotté F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM.
    J Clin Oncol; 2005 May 20; 23(15):3343-51. PubMed ID: 15738542
    [Abstract] [Full Text] [Related]

  • 6. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
    Hussain M, Petrylak D, Fisher E, Tangen C, Crawford D.
    Semin Oncol; 1999 Oct 20; 26(5 Suppl 17):55-60. PubMed ID: 10604271
    [Abstract] [Full Text] [Related]

  • 7. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
    Oh WK, Hagmann E, Manola J, George DJ, Gilligan TD, Jacobson JO, Smith MR, Kaufman DS, Kantoff PW.
    Clin Cancer Res; 2005 Jan 01; 11(1):284-9. PubMed ID: 15671557
    [Abstract] [Full Text] [Related]

  • 8. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.
    Petrylak DP, Macarthur R, O'Connor J, Shelton G, Weitzman A, Judge T, England-Owen C, Zuech N, Pfaff C, Newhouse J, Bagiella E, Hetjan D, Sawczuk I, Benson M, Olsson C.
    Semin Oncol; 1999 Oct 01; 26(5 Suppl 17):28-33. PubMed ID: 10604266
    [Abstract] [Full Text] [Related]

  • 9. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.
    Savarese D, Taplin ME, Halabi S, Hars V, Kreis W, Vogelzang N.
    Semin Oncol; 1999 Oct 01; 26(5 Suppl 17):39-44. PubMed ID: 10604268
    [Abstract] [Full Text] [Related]

  • 10. Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer.
    Sinibaldi VJ, Carducci M, Laufer M, Eisenberger M.
    Semin Oncol; 1999 Oct 01; 26(5 Suppl 17):45-8. PubMed ID: 10604269
    [Abstract] [Full Text] [Related]

  • 11. Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms.
    Legrier ME, Oudard S, Judde JG, Guyader C, de Pinieux G, Boyé K, de Cremoux P, Dutrillaux B, Poupon MF.
    Br J Cancer; 2007 Jan 29; 96(2):269-76. PubMed ID: 17211467
    [Abstract] [Full Text] [Related]

  • 12. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.
    Fizazi K, Sikes CR, Kim J, Yang J, Martinez LA, Olive MC, Logothetis CJ, Navone NM.
    Anticancer Res; 2004 Jan 29; 24(5A):2897-903. PubMed ID: 15517894
    [Abstract] [Full Text] [Related]

  • 13. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?
    Michels J, Montemurro T, Murray N, Kollmannsberger C, Nguyen Chi K.
    Cancer; 2006 Mar 01; 106(5):1041-6. PubMed ID: 16456811
    [Abstract] [Full Text] [Related]

  • 14. Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer.
    Kreis W, Budman D.
    Semin Oncol; 1999 Oct 01; 26(5 Suppl 17):34-8. PubMed ID: 10604267
    [Abstract] [Full Text] [Related]

  • 15. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E, Bozas G, Kostakopoulos A, Kastritis E, Deliveliotis C, Antoniou N, Skarlos D, Papadimitriou C, Dimopoulos MA, Bamias A.
    Urology; 2005 Jan 01; 65(1):126-30. PubMed ID: 15667877
    [Abstract] [Full Text] [Related]

  • 16. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
    Figg WD, Li H, Sissung T, Retter A, Wu S, Gulley JL, Arlen P, Wright JJ, Parnes H, Fedenko K, Latham L, Steinberg SM, Jones E, Chen C, Dahut W.
    BJU Int; 2007 May 01; 99(5):1047-55. PubMed ID: 17437439
    [Abstract] [Full Text] [Related]

  • 17. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
    Nelius T, Klatte T, Yap R, Kalinski T, Röpke A, Filleur S, Allhoff EP.
    BJU Int; 2006 Sep 01; 98(3):580-5. PubMed ID: 16925757
    [Abstract] [Full Text] [Related]

  • 18. Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model.
    Miyake H, Hara S, Arakawa S, Kamidono S, Hara I.
    Br J Cancer; 2001 Mar 23; 84(6):859-63. PubMed ID: 11259104
    [Abstract] [Full Text] [Related]

  • 19. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.
    BJU Int; 2012 Oct 23; 110(8):1149-55. PubMed ID: 22369348
    [Abstract] [Full Text] [Related]

  • 20. Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer.
    Wilding G, Soulie P, Trump D, Das-Gupta A, Small E.
    Cancer; 2006 May 01; 106(9):1917-24. PubMed ID: 16568471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.